Literature DB >> 464351

Non-compliance in asthmatic children: a study of theophylline levels in a pediatric emergency room population.

J L Sublett, S J Pollard, G J Kadlec, J M Karibo.   

Abstract

Sub-therapeutic theophylline levels due to patient (parent) non-compliance is a significant cause of outpatient treatment failure in childhood asthma. In a study of 50 known asthmatic children with acute asthmatic episodes, 98% had sub-therapeutic theophylline levels less than 10 mcg/ml with 75.5% due to inadequate patient (parent) compliance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464351

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  7 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  Use of MP3 players to increase asthma knowledge in inner-city African-American adolescents.

Authors:  Giselle S Mosnaim; Marc S Cohen; Christopher H Rhoads; Sarah Stuart Rittner; Lynda H Powell
Journal:  Int J Behav Med       Date:  2008

3.  Factors associated with emergency department visits by children with asthma: implications for health education.

Authors:  Y Wasilewski; N M Clark; D Evans; M J Levison; B Levin; R B Mellins
Journal:  Am J Public Health       Date:  1996-10       Impact factor: 9.308

4.  Acceptance of domiciliary theophylline monitoring using dried blood spots.

Authors:  J M Rattenbury; J Tsanakas
Journal:  Arch Dis Child       Date:  1988-12       Impact factor: 3.791

Review 5.  Theophylline.

Authors:  E F Ellis
Journal:  Clin Rev Allergy       Date:  1983-03

Review 6.  Compliance with medical regimens, self-management programs, and self-care in childhood asthma.

Authors:  E L Klingelhofer
Journal:  Clin Rev Allergy       Date:  1987-08

7.  Patient compliance with oral theophylline therapy.

Authors:  D R Taylor; C D Kinney; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.